|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Overall (N = 114)** | **Treatment group** | **P-value\*** |
|   |   | Placebo (N = 59) | Gabapentin (N = 55) |   |
| Age Mean (SD) | 59.6 (12.0) | 59.4 (11.1) | 59.8 (12.9) | 0.87\*\* |
| Race/ethnicity |   |   |   | 0.94 |
| Non-Hispanic White | 103 (90.4%) | 54 (91.5%) | 49 (89.1%) |   |
| Non-Hispanic Black | 6 (5.3%) | 3 (5.1%) | 3 (5.5%) |   |
| Hispanic or Latino | 4 (3.5%) | 2 (3.4%) | 2 (3.6%) |   |
| Asian | 1 (0.9%) | 0 | 1 (1.8%) |   |
| BMI Mean (SD) | 29.1 (5.8) | 28.7 (5.7) | 29.6 (6.0) | 0.33\*\* |
| Tobacco Use |   |   |   | 0.59 |
| Current | 5 (4.4%) | 3 (5.1%) | 2 (3.6%) |   |
| Former | 23 (20.2%) | 14 (23.7%) | 9 (16.4%) |   |
| Never | 86 (75.4%) | 42 (71.2%) | 44 (80%) |   |
| Menopausal status |   |   |   | 0.83 |
| Pre-menopausal | 29 (24.6%) | 15 (25.4%) | 13 (23.6%) |   |
| Post-menopausal | 86 (75.4%) | 44 (74.6%) | 42 (76.4%) |   |
| Number of prior abdominal/pelvic surgeriesMedian (q1-q3) |  1 (0-2) |  1 (0-2) |  1 (0-2) |  0.86\*\*\* |
| Stage of prolapse |   |   |   | 0.08 |
| I | 1 (0.9%) | 0 | 1 (1.8%) |   |
| II | 35 (30.7%) | 13 (22%) | 22 (40%) |   |
| III | 63 (55.3%) | 36 (61%) | 27 (49.1%) |   |
| IV | 15 (13.2%) | 10 (17%) | 5 (9.1%) |   |
| Charlson comorbidity index Mean (SD) | 2.0 (1.3) | 2.1 (1.3) | 1.8 (1.4) | 0.39\*\* |
| Type of surgery |   |   |   | 0.24 |
| Obliterative | 15 (13.2%) | 9 (15.2%) | 6 (10.9%) |   |
| Native-tissue vaginal | 25 (21.9%) | 12 (20.3%) | 13 (23.6%) |   |
| Native tissue laparoscopic | 23 (20.2%) | 8 (13.6%) | 15 (27.3%) |   |
| Mesh-augmented laparoscopic | 51 (44.7%) | 30 (50.9%) | 21 (28.2%) |   |
| Estimated blood loss (mL) Median (q1-q3) | 150 (100-200) | 150 (100-200) | 150 (100-200) | 0.38\*\*\* |
| ASA class |   |   |   | 0.01 |
| 1 | 5 (4.4%) | 0 | 5 (9.1%) |   |
| 2 | 84 (72.7%) | 41 (69.5%) | 43 (78.2%) |   |
| 3 | 25 (21.9%) | 18 (30.5%) | 7 (12.7%) |   |
| Duration of surgery (hours) Mean (SD) | 3.5 (1.1) | 3.6 (1.1) | 3.5 (1.1) | 0.40\*\* |
| Pain at 12 hours after arrival to floor Median (q1-q3) | 0 (0-3) | 0 (0-3) | 0 (0-3) | 0.31\*\*\* |
| Pain, highest recorded Median (q1-q3) | 6.5 (4-8) | 6 (5-8) | 7 (4-8) | 0.57\*\*\* |
| Antiemetics (number used) Median (q1-q3) | 0 (0-1) | 0 (0-1) | 0 (0-1) | 0.34\*\*\* |
| Stanford Sleepiness Scale |   |   |   | 0.58 |
| Feeling active, vital, alert, or wide awake | 28 (28.6%) | 13 (27.1%) | 15 (30%) |   |
| Functioning at high levels, but not at peak; able to concentrate |  34 (34.7%) |  19 (39.6%) |  15 (30%) |   |
| Awake, but relaxed; responsive but not fully alert |  20 (20.4%) |  8 (16.7%) |  12 (24%) |   |
| Somewhat foggy, let down | 8 (8.2%) | 5 (10.4%) | 3 (6%) |   |
| Foggy; losing interest in remaining awake; slowed down |  3 (3.1%) |  2 (4.2%) |  1 (2%) |   |
| Sleep, woozy, fighting sleep; prefer to lie down |  5 (5.1%) |  1 (2.1%) |  4 (8%) |   |
| No longer fight sleep, sleep onset soon, having dream-like thoughts |  0 |  0 |  0 |   |
| Missing | 16 | 16 |   |
| Length of hospital stay (hours) Mean (SD) | 31.9 (6.3) | 32.8 (7.6) | 31.0 (4.3) | 0.10\*\* |
| Total morphine milligram equivalents used after arrival to floor (MME) Median (q1-q3) |  31.2 (28.8-33.6) |  15 (0-30) |  7.5 (0-22.5) |  0.09\*\*\* |
| Opioid prescription at discharge |   |   |   | 0.57 |
| No | 80 (70.2%) | 40 (67.8%) | 40 (72.7%) |   |
| Yes | 34 (29.8%) | 19 (32.2%) | 15 (27.3%) |   |
| Opioid prescription refill/new prescription requested within 6 weeks |   |   |   |  0.49 |
| No | 99 (86.8%) | 50 (84.7%) | 49 (89.1%) |   |
| Yes | 15 (13.2%) | 9 (15.3%) | 6 (10.9%) |   |

\*P-Value obtained from a chi-square test or Fishers’ exact test. \*\*P-value obtained from a t-test. \*\*\*P-value obtained from Wilcoxon rank sum test.